These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 37819557)

  • 41. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
    Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
    J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disruption of nuclear envelope integrity as a possible initiating event in tauopathies.
    Prissette M; Fury W; Koss M; Racioppi C; Fedorova D; Dragileva E; Clarke G; Pohl T; Dugan J; Ahrens D; Chiu J; Hunt C; Siao CJ; Young T; Bhowmick A; Rogulin V; Desclaux M; Hayden EY; Podgorski M; Gao M; Macdonald LE; Frendewey D; Yancopoulos GD; Zambrowicz B
    Cell Rep; 2022 Aug; 40(8):111249. PubMed ID: 36001963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tau alteration and neuronal degeneration in tauopathies: mechanisms and models.
    Brandt R; Hundelt M; Shahani N
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):331-54. PubMed ID: 15615650
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design.
    Wang D; Huang X; Yan L; Zhou L; Yan C; Wu J; Su Z; Huang Y
    Protein J; 2021 Oct; 40(5):656-668. PubMed ID: 34401998
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An acetylation-phosphorylation switch that regulates tau aggregation propensity and function.
    Carlomagno Y; Chung DC; Yue M; Castanedes-Casey M; Madden BJ; Dunmore J; Tong J; DeTure M; Dickson DW; Petrucelli L; Cook C
    J Biol Chem; 2017 Sep; 292(37):15277-15286. PubMed ID: 28760828
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
    J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Annexins A2 and A6 interact with the extreme N terminus of tau and thereby contribute to tau's axonal localization.
    Gauthier-Kemper A; Suárez Alonso M; Sündermann F; Niewidok B; Fernandez MP; Bakota L; Heinisch JJ; Brandt R
    J Biol Chem; 2018 May; 293(21):8065-8076. PubMed ID: 29636414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased acetylation of microtubules rescues human tau-induced microtubule defects and neuromuscular junction abnormalities in
    Mao CX; Wen X; Jin S; Zhang YQ
    Dis Model Mech; 2017 Oct; 10(10):1245-1252. PubMed ID: 28819043
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Further understanding of tau phosphorylation: implications for therapy.
    Medina M; Avila J
    Expert Rev Neurother; 2015 Jan; 15(1):115-22. PubMed ID: 25555397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation.
    Grinberg LT; Wang X; Wang C; Sohn PD; Theofilas P; Sidhu M; Arevalo JB; Heinsen H; Huang EJ; Rosen H; Miller BL; Gan L; Seeley WW
    Acta Neuropathol; 2013 Apr; 125(4):581-93. PubMed ID: 23371364
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
    Mocanu MM; Nissen A; Eckermann K; Khlistunova I; Biernat J; Drexler D; Petrova O; Schönig K; Bujard H; Mandelkow E; Zhou L; Rune G; Mandelkow EM
    J Neurosci; 2008 Jan; 28(3):737-48. PubMed ID: 18199773
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.
    Brunden KR; Ballatore C; Crowe A; Smith AB; Lee VM; Trojanowski JQ
    Exp Neurol; 2010 Jun; 223(2):304-10. PubMed ID: 19744482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tau: It's Not What You Think.
    Baas PW; Qiang L
    Trends Cell Biol; 2019 Jun; 29(6):452-461. PubMed ID: 30929793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assembly of filamentous tau aggregates in human neuronal cells.
    Ko LW; Rush T; Sahara N; Kersh JS; Easson C; Deture M; Lin WL; Connor YD; Yen SH
    J Alzheimers Dis; 2004 Dec; 6(6):605-22; discussion 673-81. PubMed ID: 15665401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. O-GlcNAc modification and the tauopathies: insights from chemical biology.
    Yuzwa SA; Vocadlo DJ
    Curr Alzheimer Res; 2009 Oct; 6(5):451-4. PubMed ID: 19874270
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
    Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
    J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.
    Congdon EE; Lin Y; Rajamohamedsait HB; Shamir DB; Krishnaswamy S; Rajamohamedsait WJ; Rasool S; Gonzalez V; Levenga J; Gu J; Hoeffer C; Sigurdsson EM
    Mol Neurodegener; 2016 Aug; 11(1):62. PubMed ID: 27578006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.